Charlie'S Holdings, Inc. (CHUC) — SEC Filings
Charlie'S Holdings, Inc. (CHUC) — 19 SEC filings. Latest: 10-Q (Nov 19, 2025). Includes 7 8-K, 6 10-Q, 2 DEF 14A.
View Charlie'S Holdings, Inc. on SEC EDGAR
Overview
Charlie'S Holdings, Inc. (CHUC) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 19, 2025: Charlie's Holdings, Inc. (CHUC) reported a significant turnaround for the nine months ended September 30, 2025, achieving a net income of $4.368 million, a substantial improvement from a net loss of $3.034 million in the prior year period. This was primarily driven by a gain of $7.500 million from t
Sentiment Summary
Across 19 filings, the sentiment breakdown is: 2 bearish, 15 neutral, 2 mixed. The dominant filing sentiment for Charlie'S Holdings, Inc. is neutral.
Filing Type Overview
Charlie'S Holdings, Inc. (CHUC) has filed 6 10-Q, 7 8-K, 2 DEF 14A, 2 10-K, 2 SC 13G/A with the SEC between Feb 2024 to Nov 2025.
Filings by Year
Recent SEC Filings (19)
Risk Profile
Risk Assessment: Of CHUC's 18 recent filings, 4 were flagged as high-risk, 10 as medium-risk, and 4 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $11.934M |
| Net Income | $4.368M |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $1.150M |
| Operating Margin | N/A |
| Total Assets | $10.558M |
| Total Debt | $7.319M |
Key Executives
- Michael King
- PEO
- Non-PEO NEO
Industry Context
The vapor and tobacco product industry is highly regulated, with evolving FDA oversight impacting product approvals and market access. Companies are increasingly focused on product innovation and navigating complex compliance landscapes. The market also sees consolidation and strategic partnerships, as evidenced by the IP sale to R.J. Reynolds Vapor Company.
Top Tags
financials (6) · Vapor Products (3) · Going Concern (3) · acquisition (3) · material-agreement (3) · 10-Q (3) · FDA Regulation (2) · Regulatory Risk (2) · Medicinal Chemicals (2) · Net Loss (2)
Executive Compensation
From the most recent DEF 14A filing (Jun 24, 2025):
- Not Disclosed — Principal Executive Officer: $0
- Not Disclosed — Principal Financial Officer: $0
- Not Disclosed — Other Named Executive Officers (PEO): $0
- Not Disclosed — Non-PEO NEOs: $0
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Income | $4.368M | for the nine months ended September 30, 2025, compared to a $3.034M net loss in 2024 |
| Gain on Sale of Intellectual Property | $7.500M | from the sale of PACHA synthetic products to R.J. Reynolds Vapor Company |
| Product Revenue | $11.934M | for the nine months ended September 30, 2025, up from $6.718M in 2024 |
| Revenue Increase | 77.6% | year-over-year for the nine months ended September 30, 2025 |
| Net Cash Used in Operating Activities | $6.172M | for the nine months ended September 30, 2025 |
| Working Capital | $3.079M | as of September 30, 2025, an increase from a $1.855M deficit at December 31, 2024 |
| Cash | $1,150 | as of September 30, 2025, up from $211 at December 31, 2024 (in thousands) |
| Loss from Operations | $2,042,000 | for the nine months ended September 30, 2025 |
| Gain on PMTA Asset Sale | $6.5M | Key driver of net income and improved liquidity. |
| Common Shares Outstanding | 262,434,864 | As of August 21, 2025, indicating potential dilution. |
| Salary Reductions | 50% | Cost-cutting measure for officers and managers. |
| Contingent Payment | $4.2M | Potential additional payment from asset sale based on product sales. |
| Net Loss | $1.5M | for the three months ended March 31, 2025, up from $0.9M in Q1 2024 |
| Note Payable | $1.5M | due to Michael King by April 28, 2025 |
| Loan Payable | $1.0M | due by April 28, 2025 |
Forward-Looking Statements
- {"claim":"The market may react neutrally to slightly negatively to the slight reduction in Iroquois Capital Management's stake, as it's an amendment and still a significant holding.","entity":"Charlie's Holdings, Inc. stock price","targetDate":"February 13, 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Charlie'S Holdings, Inc. (CHUC)?
Charlie'S Holdings, Inc. has 19 recent SEC filings from Feb 2024 to Nov 2025, including 7 8-K, 6 10-Q, 2 DEF 14A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of CHUC filings?
Across 19 filings, the sentiment breakdown is: 2 bearish, 15 neutral, 2 mixed. The dominant sentiment is neutral.
Where can I find Charlie'S Holdings, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Charlie'S Holdings, Inc. (CHUC) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Charlie'S Holdings, Inc.?
Key financial highlights from Charlie'S Holdings, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for CHUC?
The investment thesis for CHUC includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Charlie'S Holdings, Inc.?
Key executives identified across Charlie'S Holdings, Inc.'s filings include Michael King, PEO, Non-PEO NEO.
What are the main risk factors for Charlie'S Holdings, Inc. stock?
Of CHUC's 18 assessed filings, 4 were flagged high-risk, 10 medium-risk, and 4 low-risk.
What are recent predictions and forward guidance from Charlie'S Holdings, Inc.?
Recent forward-looking statements from Charlie'S Holdings, Inc. include guidance on {"claim":"The market may react neutrally to slightly negatively to the slight reduction in Iroquois Capital Management's.